BG
BIVV

Bellevue Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Bellevue Group’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,200
Closed -$550K – 139
2017
Q4 		$550K Sell
10,200
-12,550
-55% -$687K 0.06% 121
2017
Q3 		$1.3M Hold
22,750
– – 0.14% 102
2017
Q2 		$1.37M Hold
22,750
– – 0.16% 94
2017
Q1 		$1.24M Buy
+22,750
New +$1.12M 0.17% 93

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Bellevue Group's BIVV Position: Q1 2018 in Review

Bellevue Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 10,200 shares — an estimated $550K sold.

Bellevue Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $1.37M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Bellevue Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Bellevue Group sold 10,200 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $550K.
  • Bellevue Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Bellevue Group's Bioverativ Inc. Common Stock position peaked at $1.37M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.